Letters sent to healthcare professionals in February 2018

Letters were sent about ellaOne, ERWINASE, Eperzanâ–¼, Ocalivaâ–¼, Velcade, Esmya, and Bleo-Kyowa.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 8 March 2018

• Therapeutic area: Anaesthesia and intensive care, Cancer, Cardiovascular disease and lipidology, Endocrinology, diabetology and metabolism and GI, hepatology and pancreatic disorders
  Show 7 more
  Haematology and oncology, Immunosuppression and transplantation, Infectious disease, Neurology, Obstetrics, gynaecology and fertility, Paediatrics and neonatology, and Urology and nephrology

In February 2018, letters were sent to healthcare professionals about:

• ellaOne post-marketing surveillance:
• Ocalivaâ–¼ (obeticholic acid):
• ERWINASE:
• Bleo-Kyowa (bleomycin sulphate), powder for solution for injection 바카라 사이트“ 바카라 사이트“ see Class 4 Medicine Defect Information alert
• Velcade (bortezomib) 3.5 mg vials:
• Restrictions on the use of ulipristal acetate, Esmya 5 mg tablet,
• ·¡±è±ð°ù³ú²¹²Ôâ–¼(²¹±ô²ú¾±²µ±ô³Ü³Ù¾±»å±ð):

Article citation: Drug Safety Update volume 11 issue 8; March 2018: 5.

Published 8 March 2018